BioCryst Pharmaceuticals BCRX Foreign
Foreign at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CurrentForeignTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's foreign.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's foreign?
- BioCryst Pharmaceuticals (BCRX) reported foreign of $310K in Q4 2025.
- How has BioCryst Pharmaceuticals's foreign changed year-over-year?
- BioCryst Pharmaceuticals's foreign increased by 6.6% year-over-year, from $290.75K to $310K.
- What is the long-term trend for BioCryst Pharmaceuticals's foreign?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's foreign has grown at a 51.9% compound annual growth rate (CAGR), from $233K to $1.24M.
- What does foreign mean?
- The current income tax expense or benefit payable to foreign governments on income earned in international jurisdictions. This represents the immediate tax impact of global operations and is essential for reconciling the global effective tax rate. It helps investors understand the tax implications of the company's international business strategy.